Deep Interpretation of Pharmaceutical Intermediates Industry

      First, the industry overview 1, the industry profile Pharmaceutical intermediates industry refers to those in accordance with strict quality standards with chemical synthesis or biosynthesis method for the pharmaceutical production and processing of finished products for the manufacture of organic / inorganic intermediates or API drug companies. Here the pharmaceutical intermediates are divided into CMO, CRO two sub-sectors. CMO: Contract Manufacturing Organization refers to the contract manufacturing enterprises, that is, pharmaceutical companies will be part of the production outsourcing to the partners. Pharmaceutical CMO industry chain is generally starting from the special pharmaceutical raw materials. Industry companies need to purchase basic chemical raw materials and classified into specialized pharmaceutical raw materials, and then gradually form the raw materials to start raw materials, cGMP intermediates, APIs and preparations. At present, the major multinational pharmaceutical companies tend to establish a long-term strategic partnership with a small number of core suppliers, the company's survival within the industry through its partners basically at a glance. CRO: Contract (Clinical) Research Organization refers to the contract research institutions, pharmaceutical companies will be part of the research outsourcing to partners. At present, the industry mainly to custom production, custom research and development and pharmaceutical contract research and sales as the main mode of cooperation, no matter what way, regardless of whether the pharmaceutical intermediates for innovative products, the core competitiveness of enterprises is still to research and development technology as the first Elements, the side reflects the company's downstream customers or partners.2, the industry scale, the pace of development, major manufacturers and other professional medical research advisory agency IMS Health Incorporated data show that the global pharmaceutical market in 2012 reached 959 billion US dollars, is expected in 2017 the global pharmaceutical market will reach 1.2 trillion US dollars, according to projections 2012 - 2017 global pharmaceutical market average annual compound growth rate of 4.6%. The global pharmaceutical market is about 18 times the size of the global pesticide market. In 2010, the global pharmaceutical custom R & D and production industry market size of 24 billion US dollars, accounting for the same period the global pharmaceutical market size of 2.80%. 2011 - 2014, the global pharmaceutical custom R & D and production industry will maintain an average annual compound growth rate of 8.86%, higher than the growth rate of the global pharmaceutical market over the same period. In 2010, China's pharmaceutical R & D production scale was US $ 1.7 billion, which is expected to grow to US $ 3.1 billion by 2015, with an average compound annual growth rate of 12.77%. Combined with the relevant information of domestic listed companies, large manufacturers to custom production as the main business model, in the custom production mode, large customers and suppliers between the cooperative relationship is relatively stable, and the closer cooperation, the higher the degree of trust, The more cooperation will be provided. Replacement of suppliers need a long period of inspection period, therefore, as a strong sticky business, pharmaceutical intermediates industry enterprises at this stage the main direction for foreign well-known pharmaceutical companies. From the current perspective, the scale of domestic pharmaceutical intermediates industry is only tens of billions of dollars, the global scale is tens of billions of dollars. But taking into account the competitor of the company's products are mostly 2-3, the company once into the pharmaceutical giant's core supplier system, both in the scale of production or gross margin are maintained in a fairly stable state. Personally believe that the current external environment is not yet conditional to rely on environmental protection to reduce the supply side to the advantages of technology and cost to win the desert flower business, more likely to rely on technological advantages to form the advantages of scale, and then open up the upstream industry chain, forming a Breakdown of the pharmaceutical industry leading enterprises.Some domestic and foreign manufacturers:Among them, the bo teng shares although r&d and production in the global medical custom business market share only 0.34%, but in income accounted for 1%, has formed a certain influence. Another part of the listed companies benefit from the upstream costs down and customized production, in recent years, gradually expand the scale of production of pharmaceutical intermediates related products, pharmaceutical intermediates industry progresses day by day. Here a bit about the pesticide intermediates and pharmaceutical intermediates related (part of the company has, in the two pieces and higher proportion of pesticide intermediates). Pharmaceutical intermediates market capacity (about 180 billion yuan) is a pesticide intermediates (about 50 billion yuan) more than three times. Pesticide intermediates and pharmaceutical intermediates, both in common, and have obvious difference. Have in common is pesticide intermediates and pharmaceutical intermediates customers overlap degree is high, technical overlapping degree is higher also. Differences are pharmaceutical intermediates is a requirements more stringent business, for example, production process must comply with GMP standard. industry market structure analysis supply and demand in 2010-2020, the global pharmaceutical market will usher in a wave of Patent expirations * *, of which 2013-2020 patents expire a year an average of more than 200 varieties, international calls "Patent Cliff (Patent Cliff). Since 2000, the global generic-drugs market growth lasts for more than the growth of the whole medicine market, its growth speed is more than double Patent medicine. 2013 global generic-drugs market is expected to reach $180 billion, according to the estimated 2005-2013, the global generic-drugs market scale is expected to reach a CAGR of 14.7%. The relevant authorities to predict the future five years the global generics market size will be increasing at the rate of 10% to 14%, far higher than 4% to 6% of the entire pharmaceutical industry expected growth. It follows that the generics market development will significantly promote the development of pharmaceutical intermediates industry. European and American customers due to the environmental protection, cost, the original drug patents expire more willing to put some factors such as production technology transfer to China, with the domestic local rapid rise of the production capacity and research and development capacity and the intermediate of the features of many varieties, small batch, pharmaceutical intermediates company has the ability to receive, and in related synthesis process for postpartum, scale advantage. 2, main products of domestic manufacturers and in investment projects (subject to pharmaceutical intermediates as the research object, by the following data are harvesting company related data) in pharmaceutical intermediates. Jas this chemistry: main products include antitumor drug intermediates, antiepileptic drug intermediates and antiviral intermediates. The antiepileptic drug intermediates ABAH has in October 2014 formally put into production, production capacity of 1000 tons, according to the China international capital corporation to provide data, thickening of the project profit is expected to more than 30 million yuan. Otherwise pesticide intermediates (project thickness increases the profit of 100 million yuan of above).